Kangnuya: Kangyuedna included in the national basic medical insurance drug list

Kangnoa announced that the company's independently developed Class 1 new drug Kangyueda has been included in the "National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List". Kangyueda has currently been approved for three indications: adults with moderate to severe atopic dermatitis who have poor control with or are unsuitable for topical therapy, chronic sinusitis with nasal polyps that are poorly controlled with glucocorticoids and/or surgical treatment, and adults with moderate to severe seasonal allergic rhinitis whose symptoms are poorly controlled after treatment with nasal glucocorticoids combined with antihistamines. All three indications have been included in the new medical insurance catalog.